Baxter International, Inc. Highlights Commitment To Innovation And Focus On Improving Patient Outcomes At WFH World Congress

Published: May 12, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX) showcased its commitment to innovation in hemophilia today with the presentation of new data from 60 oral and poster presentations during the 2014 World Federation of Hemophilia (WFH) World Congress in Melbourne, Australia (May 11-15). The data include safety, efficacy and immunogenicity findings on Baxter’s global leading brands and new treatments for hemophilia A, von Willebrand disease and other coagulation disorders.

Help employers find you! Check out all the jobs and post your resume.

Back to news